Wellspring
This article was originally published in The Tan Sheet
Executive Summary
Neptune, N.J.-based firm completes acquisition of Shire Pharmaceutical Group's Canadian OTC product line, company announces Sept. 4. OTC line includes over 12 products ranging from laxatives to an anti-fungal cream to potassium supplements and will be produced in a recently acquired (also from Shire) Oakville, Ontario plant. Line will serve as springboard for expansion into U.S., Wellspring says. Company will "relaunch these products...with a renewed marketing push" and plans to reintroduce several discontinued Shire products. Later this year, Wellspring also will add "at least one new OTC brand for treatment of several different and common gastrointestinal disorders"
You may also be interested in...
WellSpring To Make U.S. Debut With Acquisition Of McNeil’s Micatin, Emetrol
WellSpring Pharmaceutical Corporation will enter the U.S. OTC market with its purchase of the U.S. rights to several smaller brands from McNeil Consumer Healthcare
WellSpring To Make U.S. Debut With Acquisition Of McNeil’s Micatin, Emetrol
WellSpring Pharmaceutical Corporation will enter the U.S. OTC market with its purchase of the U.S. rights to several smaller brands from McNeil Consumer Healthcare
WellSpring To Make U.S. Debut With Acquisition Of McNeil’s Micatin, Emetrol
WellSpring Pharmaceutical Corporation will enter the U.S. OTC market with its purchase of the U.S. rights to several smaller brands from McNeil Consumer Healthcare